Please reload

Recent Posts

The drug rebate curtain

July 20, 2018

Please reload

Featured Posts

Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends

September 12, 2017

  • A Johnson & Johnson pharmaceutical unit focused on the development of hepatitis C research said it will end its program amid a crowded market.

  • Janssen Sciences Ireland cited the increasing availability of a number of highly effective therapies addressing the medical need.

Getty Images


Shares of biotech company Achillion Pharmaceuticals were more than 20 percent lower Monday in premarket trading after it announced its hepatitis C collaboration with a Johnson & Johnson pharmaceutical unit ended.


Johnson & Johnson was down slightly in premarket trading after its Janssen Sciences Ireland said it would discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178 amid a crowded market.


Janssen said there is an increasing availability of a number of highly effective therapies addressing the medical need. Hepatitis C is a contagious liver disease which affects about 3.2 million Americans, according to the Centers for Disease Control and Prevention.


In a statement Monday, Achillion President and CEO Milind Deshpande said he was "disappointed" by the Janssen decision, given the positive data presented in a recent study.


Ongoing phase two studies with JNJ-4178 will be completed as planned, Janssen said in a statement, but will cease thereafter.


"Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists," Lawrence Blatt, global therapeutic area head, infectious disease therapeutics, Janssen, said in a statement.


Source: CNBC


Share on Facebook
Share on Twitter
Please reload

Follow Us
Please reload

Search By Tags
Please reload

  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Social Icon
  • Black Facebook Icon
  • Black Twitter Icon
  • Black LinkedIn Icon
  • Black Google+ Icon